PURPOSE: To report and analyze long-term best-corrected visual acuity (BCVA) outcomes following a free autologous retinal pigment epithelium (RPE)-choroid graft translocation in patients with exudative age-related macular degeneration (AMD). DESIGN: Prospective cohort study. SETTING: Institutional. STUDY POPULATION: One hundred and thirty consecutive patients (133 eyes) with AMD underwent RPE-choroid graft translocation between October 2001 and February 2006. All patients had a subfoveal choroidal neovascular membrane with or without hemorrhage and/or an RPE tear. All were either ineligible for or nonresponsive to photodynamic therapy, the standard treatment at the time of surgery. OBSERVATION PROCEDURES: Data collection included preoperative and postoperative visual acuity measurements, fundus photography, fluorescein and indocyanine green angiography, and microperimetry. MAIN OUTCOME MEASURES: Postoperative BCVA. RESULTS: The mean preoperative BCVA was 20/250. Four years after surgery, 15% of the eyes had a BCVA of >20/200, and 5% had a BCVA of ≥20/40. One patient achieved a BCVA of 20/32, which was maintained at 7 years after surgery. Complications consisted of proliferative vitreoretinopathy (n = 13), recurrent neovascularization (n = 13), and hypotony (n = 2). CONCLUSIONS: RPE-choroid graft transplantation may maintain macular function for up to 7 years after surgery, with relatively low complication and recurrence rates. Retinal sensitivity, BCVA data, and fixation on the graft suggest that the graft, rather than simply the removal of submacular hemorrhage and/or choroidal neovascular membrane, was responsible for the preservation of macular function. This surgery may be an alternative for patients with AMD who cannot undergo other standard treatment.
PURPOSE: To report and analyze long-term best-corrected visual acuity (BCVA) outcomes following a free autologous retinal pigment epithelium (RPE)-choroid graft translocation in patients with exudative age-related macular degeneration (AMD). DESIGN: Prospective cohort study. SETTING: Institutional. STUDY POPULATION: One hundred and thirty consecutive patients (133 eyes) with AMD underwent RPE-choroid graft translocation between October 2001 and February 2006. All patients had a subfoveal choroidal neovascular membrane with or without hemorrhage and/or an RPE tear. All were either ineligible for or nonresponsive to photodynamic therapy, the standard treatment at the time of surgery. OBSERVATION PROCEDURES: Data collection included preoperative and postoperative visual acuity measurements, fundus photography, fluorescein and indocyanine green angiography, and microperimetry. MAIN OUTCOME MEASURES: Postoperative BCVA. RESULTS: The mean preoperative BCVA was 20/250. Four years after surgery, 15% of the eyes had a BCVA of >20/200, and 5% had a BCVA of ≥20/40. One patient achieved a BCVA of 20/32, which was maintained at 7 years after surgery. Complications consisted of proliferative vitreoretinopathy (n = 13), recurrent neovascularization (n = 13), and hypotony (n = 2). CONCLUSIONS: RPE-choroid graft transplantation may maintain macular function for up to 7 years after surgery, with relatively low complication and recurrence rates. Retinal sensitivity, BCVA data, and fixation on the graft suggest that the graft, rather than simply the removal of submacular hemorrhage and/or choroidal neovascular membrane, was responsible for the preservation of macular function. This surgery may be an alternative for patients with AMD who cannot undergo other standard treatment.
Authors: Lyndon da Cruz; Kate Fynes; Odysseas Georgiadis; Julie Kerby; Yvonne H Luo; Ahmad Ahmado; Amanda Vernon; Julie T Daniels; Britta Nommiste; Shazeen M Hasan; Sakina B Gooljar; Amanda-Jayne F Carr; Anthony Vugler; Conor M Ramsden; Magda Bictash; Mike Fenster; Juliette Steer; Tricia Harbinson; Anna Wilbrey; Adnan Tufail; Gang Feng; Mark Whitlock; Anthony G Robson; Graham E Holder; Mandeep S Sagoo; Peter T Loudon; Paul Whiting; Peter J Coffey Journal: Nat Biotechnol Date: 2018-03-19 Impact factor: 54.908
Authors: Kapil Bharti; Mahendra Rao; Sara Chandros Hull; David Stroncek; Brian P Brooks; Ellen Feigal; Jan C van Meurs; Christene A Huang; Sheldon S Miller Journal: Invest Ophthalmol Vis Sci Date: 2014-02-26 Impact factor: 4.799
Authors: Jennifer H Acton; R Theodore Smith; Donald C Hood; Vivienne C Greenstein Journal: Invest Ophthalmol Vis Sci Date: 2012-11-09 Impact factor: 4.799